Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
Michael Z Liao,1 Johannes Kast,1 Marloes Berkhout,2 Hans Prenen,3 Sandeep Dutta,4 Vijay V Upreti1 1Clinical Pharmacology, Modeling & Simulation, Amgen Inc., South San Francisco, CA, USA; 2Amgen B.V., Breda, the Netherlands; 3Antwerp University Hospital, Edegem, Belgium; 4Clinical Pharmacolog...
Guardado en:
Autores principales: | Liao MZ, Kast J, Berkhout M, Prenen H, Dutta S, Upreti VV |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/25ece9ce343c4273bcedfe4dba212823 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
por: Hendrikx JJMA, et al.
Publicado: (2020) -
Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan
por: Muhammad Muaaz Munir, et al.
Publicado: (2021) -
Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
por: Chuhui Wang, et al.
Publicado: (2021) -
Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses
por: Manjunath P. Pai, et al.
Publicado: (2021) -
Estimating the no-observed-adverse-effect-level (NOAEL) of hormetic dose-response relationships in meta-data evaluations
por: Evgenios Agathokleous, et al.
Publicado: (2021)